WO2012082765A3 - Méthodes pour réduire le poids corporel et traiter le diabète - Google Patents

Méthodes pour réduire le poids corporel et traiter le diabète Download PDF

Info

Publication number
WO2012082765A3
WO2012082765A3 PCT/US2011/064690 US2011064690W WO2012082765A3 WO 2012082765 A3 WO2012082765 A3 WO 2012082765A3 US 2011064690 W US2011064690 W US 2011064690W WO 2012082765 A3 WO2012082765 A3 WO 2012082765A3
Authority
WO
WIPO (PCT)
Prior art keywords
body weight
methods
hif1α
inhibitor
treating diabetes
Prior art date
Application number
PCT/US2011/064690
Other languages
English (en)
Other versions
WO2012082765A2 (fr
Inventor
Frank J. Gonzalez
Changtao Jiang
Original Assignee
The United State Of America. As Represented By The Secretary Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United State Of America. As Represented By The Secretary Department Of Health And Human Services filed Critical The United State Of America. As Represented By The Secretary Department Of Health And Human Services
Publication of WO2012082765A2 publication Critical patent/WO2012082765A2/fr
Publication of WO2012082765A3 publication Critical patent/WO2012082765A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des méthodes pour traiter le diabète (par ex., augmenter la tolérance au glucose, réduire la résistance à l'insuline, et abaisser les lipides sériques) et/ou réduire le poids corporel (par ex., traiter le surpoids ou l'obésité), lesdites méthodes comprenant l'administration d'une quantité thérapeutiquement efficace d'une composition contenant un inhibiteur du facteur 1α inductible par l'hypoxie (HIF1α) à un sujet souffrant du diabète ou un sujet ayant besoin de réduire son poids corporel. L'inhibiteur HIF1α peut être administré en association avec un véhicule de qualité pharmaceutique. Dans certains exemples, l'inhibiteur HIF1α est administré par voie orale.
PCT/US2011/064690 2010-12-16 2011-12-13 Méthodes pour réduire le poids corporel et traiter le diabète WO2012082765A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42393610P 2010-12-16 2010-12-16
US61/423,936 2010-12-16

Publications (2)

Publication Number Publication Date
WO2012082765A2 WO2012082765A2 (fr) 2012-06-21
WO2012082765A3 true WO2012082765A3 (fr) 2012-10-11

Family

ID=45444736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/064690 WO2012082765A2 (fr) 2010-12-16 2011-12-13 Méthodes pour réduire le poids corporel et traiter le diabète

Country Status (1)

Country Link
WO (1) WO2012082765A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889608A1 (fr) 2012-10-26 2014-05-01 Nlife Therapeutics, S.L. Compositions et methodes d'administration selective de molecules d'oligonucleotides a des types de cellules
WO2020225427A1 (fr) 2019-05-09 2020-11-12 Teresa Pereira Traitement du diabète
JP2023538612A (ja) * 2020-08-18 2023-09-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 糖尿病治療及びベータ細胞再生のための方法及び組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056795A2 (fr) * 2003-12-03 2005-06-23 Corgentech, Inc. Molecules leurres d'oligonucleotides du facteur pouvant induire l'hypoxie
WO2006016143A1 (fr) * 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-kétoglutarates et leur utilisation en tant qu’agents thérapeutiques
WO2006047485A2 (fr) * 2004-10-25 2006-05-04 Henry M. Jackson Foundation Methodes visant a reduire l'expression genique induite par le hif-1
US20070253904A1 (en) * 2004-07-15 2007-11-01 Jenny Gunton Methods of treating diabetes
WO2008093086A1 (fr) * 2007-01-31 2008-08-07 Btg International Limited Modulateurs du facteur 1 inductible par hypoxie et utilisations associées
WO2009019656A1 (fr) * 2007-08-07 2009-02-12 Piramal Life Sciences Limited Dérivés de pyridyle, leur préparation et utilisation.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR100201352B1 (ko) 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
DE60128458T2 (de) 2000-03-20 2008-01-10 Massachusetts Institute Of Technology, Cambridge Anorganische teilchenkonjugate
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
CN1262542C (zh) 2001-03-30 2006-07-05 美国政府卫生与公共服务部 格尔德霉素衍生物以及其在制备治疗癌症的药物中的应用
US7081489B2 (en) 2001-08-09 2006-07-25 Florida State University Research Foundation Polymeric encapsulation of nanoparticles
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
DK2264172T3 (da) 2002-04-05 2017-11-27 Roche Innovation Ct Copenhagen As Oligomerforbindelser til modulering af HIF-1á-ekspression
US20040087556A1 (en) 2002-11-06 2004-05-06 Lynn Kirkpatrick N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
WO2004064751A2 (fr) 2003-01-16 2004-08-05 St. Johns University New York Stabilisation a base de nanoparticules de colorants fluorescents infrarouges
ATE441710T1 (de) 2003-01-31 2009-09-15 Rexahn Corp Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
WO2006052285A2 (fr) 2004-05-13 2006-05-18 The Trustees Of Columbia University In The City Of New York Nanoparticules et nanogels polymeres pour l'extraction et la liberation de composes
AU2005304112B2 (en) 2004-11-09 2009-06-04 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
ATE382337T1 (de) 2005-04-28 2008-01-15 Nipro Corp Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
CN101189020A (zh) 2005-05-10 2008-05-28 N·巴拉班 用于给予rnaⅲ-抑制肽的组合物
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
AU2009321723A1 (en) 2008-12-05 2010-06-10 Intermed Discovery Gmbh Inhibitors of HIF-1 protein accumulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056795A2 (fr) * 2003-12-03 2005-06-23 Corgentech, Inc. Molecules leurres d'oligonucleotides du facteur pouvant induire l'hypoxie
US20070253904A1 (en) * 2004-07-15 2007-11-01 Jenny Gunton Methods of treating diabetes
WO2006016143A1 (fr) * 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-kétoglutarates et leur utilisation en tant qu’agents thérapeutiques
WO2006047485A2 (fr) * 2004-10-25 2006-05-04 Henry M. Jackson Foundation Methodes visant a reduire l'expression genique induite par le hif-1
WO2008093086A1 (fr) * 2007-01-31 2008-08-07 Btg International Limited Modulateurs du facteur 1 inductible par hypoxie et utilisations associées
WO2009019656A1 (fr) * 2007-08-07 2009-02-12 Piramal Life Sciences Limited Dérivés de pyridyle, leur préparation et utilisation.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIANG CHANGTAO ET AL: "Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice.", DIABETES OCT 2011 LNKD- PUBMED:21873554, vol. 60, no. 10, October 2011 (2011-10-01), pages 2484 - 2495, XP009161927, ISSN: 1939-327X *

Also Published As

Publication number Publication date
WO2012082765A2 (fr) 2012-06-21

Similar Documents

Publication Publication Date Title
PH12018501424B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
WO2011107750A3 (fr) Administration retardée prolongée de médicament
WO2011107755A3 (fr) Administration immédiate / retardée de médicament
IL208992A (en) Use of h2 relaxin active pharmacist in the manufacture of drugs for the treatment of shortness of breath related to acute heart failure and decompensatory acute heart failure
IN2014KN00996A (fr)
WO2011127304A3 (fr) Méthodes de traitement d'un sujet en surpoids
JP2012529485A5 (ja) 赤血球凝固の予防及び治療のための組成物並びに方法
MY176863A (en) Ibat inhibitors for treatment of metabolic disorders and related conditions
WO2012068274A8 (fr) Traitement du diabète de type ii et de maladies associées au diabète par le biais de découplants mitochondriaux chimiques sûrs
NZ597666A (en) Combination therapy of an afucosylated cd20 antibody with bendamustine
UA106209C2 (en) Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid
WO2010151755A3 (fr) Traitement de maladies inflammatoires à l'aide du microarn mir-124
WO2012010966A3 (fr) Composition pharmaceutique combinée, et procédés de traitement du diabète et de troubles métaboliques
WO2012142413A3 (fr) Compositions à base de nitrite et leurs utilisations
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
IL223434A (en) Methods in n-acetylneuraminic acid, a precursor of n-acetylneuraminic acid or their combination in the preparation of a drug for the treatment of diabetic conditions and a method for determining the status of a subject in relation to nephrotic syndrome or diabetic conditions
WO2012082765A3 (fr) Méthodes pour réduire le poids corporel et traiter le diabète
Rafraf et al. Effect of l-carnitine supplementation in comparison with moderate aerobic training on insulin resistance and anthropometric indices in obese women
MX342417B (es) Composicion antioxidante para reducir el estres oxidativo atribuible al tratamiento con farmacos anticonceptivos hormonales.
WO2009005046A1 (fr) Agent thérapeutique pour colite ulcérative, comprenant de la mizoribine
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
WO2013121300A3 (fr) Procédés de traitement du psoriasis et de l'inflammation vasculaire
JP2014533689A5 (fr)
WO2012047628A3 (fr) Procédés de contrôle des taux de sucre dans le sang et compositions associées à ceux-ci

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11804860

Country of ref document: EP

Kind code of ref document: A2